aTyr Pharma, Inc. (ATYR) – What Are Researchers Saying About This Stock?

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given a consensus recommendation of “Moderate Buy” by the four ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $4.00.

A number of brokerages have issued reports on ATYR. Wall Street Zen raised aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. Wells Fargo & Company boosted their price objective on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th.

aTyr Pharma Stock Up 9.5%

aTyr Pharma stock traded up $0.57 during trading hours on Friday, hitting $6.60. 9,223 shares of the company traded hands, compared to its average volume of 65,817. aTyr Pharma has a 1-year low of $4.07 and a 1-year high of $44.40. The firm has a market cap of $16.18 million, a P/E ratio of -0.27 and a beta of 1.04. The firm’s 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $23.70.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43). On average, equities research analysts predict that aTyr Pharma will post -17.80 earnings per share for the current year.

Institutional Investors Weigh In On aTyr Pharma

An institutional investor recently bought a new stake in aTyr Pharma stock. Renaissance Technologies LLC acquired a new stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.